T1D Fund

The MBVF is a collaborative effort between the U-M Medical School’s Fast Forward Medical Innovation (FFMI) program and the U-M College of Engineering’s Center for Entrepreneurship (CFE). Founded based on an initial gift from the Monroe-Brown Foundation, MBVF makes seed-stage equity investments in UM life science startup companies, typically $100,000-$300,000. This evergreen fund serves to drive the university’s world-class leadership by creating a critical pipeline between research and the biomedical innovation life cycle, resulting in broad clinical and economic impact through startups. The Fund is exclusively for biomedical startups with U-M IP. Most applicants need to successfully complete an existing U-M translational program such as Coulter, MTRAC for Life Sciences, NSF I-Corps. Companies interested in more information should consult with the Fund Manager.

Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization. To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.

We invest in innovative early stage Life Sciences startups that address unmet needs with novel discoveries backed by strong science and competitive advantage over current options. We like to partner with founders creating breakthrough businesses in technology and healthcare. We are interested in start-ups with a unique selling point and global potential. Our focusDrug discovery Medtech Diagnostics Other life sciences AI in life sciences Investment We are happy to help you start your business from the very beginning. It is never too early for us to meet you. We approach each project individually, but our preferred option is to act as co-investor. Seed: Ready to create? We can start at € 150 K to support business creation. Series A: Ready to grow? Our sweet spot lies between € 0.5 M and € 2 M. Series B: Being exceptional? We keep a possibility of extra funding for our unicorn portfolio. Where we invest We focus mainly on Central and Eastern Europe. However, we are open to working with ambitious teams from other regions. What we offerTeam: Our team is made up of Life Science and investment professionals with years of relevant experience. We work closely with our expert partners from i&i Prague and IOCB Tech. We are ready to help if needed. Testing: We have a network of partners who evaluate and, in some cases, test technologies. We can provide valuable feedback or even confirmation of effectiveness by independent experts in the R&D field. Partnership: We value partnerships with our network of investors and potential exit partners. We believe that it is advantageous for start-ups to meet such partners at the beginning of their journey to success. We can open the door for you.

We are a European family office owned fund; we understand biosciences and medical technologies better than anyone else in the Private Equity and Venture Capital ecosystem. The capital of this fund has been generated by the family office's active bioscience investments across Europe, USA, and the APAC region since 1995. We understand the intricacies of commercializing bioscience discoveries. We also acknowledge that bioscience venture leadership requires deep courage - from founders and the investors that back them. What we look for We operate globally and only review investment opportunities submitted to us by our partner investment banks across the globe. If we believe in the transformative power of the discovery and the founder's ambition, this will suffice for us to determine the venture's potential. Our approach Upon receipt of a proposal from our investment bank partners, we will analyze the proposed deal, meet with the venture founders, and understand their vision. We will propose a deal size and structure. Execute a letter of intent and perform appropriate due diligence, negotiate, and execute a mutually acceptable binding contract. Release the required funding, close the transaction and work together to grow the business.

Address the critical bottlenecks in both established and emerging markets that limit access and affordability to novel cancer solutions. Inculcate the tenets of ESG (Environmental, Social and Governance) based investing and measure the progress and impact of our portfolio using the following metrics: E: The ability to optimize differential drug and device pricing based on geography and expand access to promising products early in their lifecycle S: Ability to boost R&D productivity through operational optimization and process transformation G: Promote ethical conduct of business and collaboration while ensuring inclusion & diversity What We DoInvest in US and EU based cancer start-ups who are keen to explore emerging markets or engage in collaborative R&D. Streamline the product-market fit and ensure access to supportive infrastructure and resources. Facilitate their collaborative R&D/commercialization strategy in geographies of interest. How We Do It Accelerate the path to successful commercialization for US and EU based start-ups developing the next generation of oncology solutions by: Reducing costs through infrastructure consolidation and collaborative expertise Expanded access to capital Facilitating rapid market penetration and commercial scaling​

Noetic invests globally to build emerging technologies in molecular therapeutics/biotech, digital health, medical devices, and wellness with a focus on mental health, pain, and other complications resulting from the central nervous system. About no•et•ic “From the Greek noēsis/ noētikos meaning inner wisdom, direct knowing, or subjective understanding” Noetic science refers to a multidisciplinary field that brings objective scientific tools and techniques together with subjective understanding to study the full range of human experience. Mission: Our mission is to nurture the scientific advancement of mental, emotional, and physiological health by investing in emerging therapies, modalities, and sciences that are committed to optimizing our human experience. Commitment: We are committed to developing sustainable therapies, products, and services that are innovative, safe, and accessible to create a better mental health landscape for current and future generations. Focus: CNS-targetted therapeutics and related sustainable solutions for mental health and physical well being.